1. Home
  2. GERN vs TRTX Comparison

GERN vs TRTX Comparison

Compare GERN & TRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.50

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Logo TPG RE Finance Trust Inc.

TRTX

TPG RE Finance Trust Inc.

HOLD

Current Price

$8.50

Market Cap

659.4M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
GERN
TRTX
Founded
1990
2014
Country
United States
United States
Employees
258
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
808.3M
659.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GERN
TRTX
Price
$1.50
$8.50
Analyst Decision
Hold
Buy
Analyst Count
3
4
Target Price
$2.17
$9.83
AVG Volume (30 Days)
14.8M
720.7K
Earning Date
05-06-2026
04-28-2026
Dividend Yield
N/A
11.55%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$26.91
$8.78
Revenue Next Year
$43.75
$4.14
P/E Ratio
N/A
$14.82
Revenue Growth
N/A
N/A
52 Week Low
$1.04
$7.57
52 Week High
$2.01
$9.85

Technical Indicators

Market Signals
Indicator
GERN
TRTX
Relative Strength Index (RSI) 65.05 52.36
Support Level $1.44 $8.48
Resistance Level $1.72 $8.72
Average True Range (ATR) 0.09 0.13
MACD 0.03 -0.01
Stochastic Oscillator 68.06 57.14

Price Performance

Historical Comparison
GERN
TRTX

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

About TRTX TPG RE Finance Trust Inc.

TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.

Share on Social Networks: